131 related articles for article (PubMed ID: 36738498)
21. VEGF/VEGFR-2 upregulates EZH2 expression in lung adenocarcinoma cells and EZH2 depletion enhances the response to platinum-based and VEGFR-2-targeted therapy.
Riquelme E; Suraokar M; Behrens C; Lin HY; Girard L; Nilsson MB; Simon G; Wang J; Coombes KR; Lee JJ; Hong WK; Heymach J; Minna JD; Wistuba II
Clin Cancer Res; 2014 Jul; 20(14):3849-61. PubMed ID: 24850841
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of EZH2 Ameliorates Sepsis Acute Lung Injury (SALI) and Non-Small-Cell Lung Cancer (NSCLC) Proliferation through the PD-L1 Pathway.
Wang Z; Guo Z; Wang X; Liao H; Chai Y; Wang Z; Wang Z
Cells; 2022 Dec; 11(24):. PubMed ID: 36552722
[TBL] [Abstract][Full Text] [Related]
23. EZH2-mediated repression of GSK-3β and TP53 promotes Wnt/β-catenin signaling-dependent cell expansion in cervical carcinoma.
Chen Q; Zheng PS; Yang WT
Oncotarget; 2016 Jun; 7(24):36115-36129. PubMed ID: 27092879
[TBL] [Abstract][Full Text] [Related]
24. EZH2 affects malignant progression and DNA damage repair of lung adenocarcinoma cells by regulating RAI2 expression.
Huang M; Ding J; Wu X; Peng X; Wu G; Peng C; Zhang H; Mao C; Huang B
Mutat Res; 2022; 825():111792. PubMed ID: 35939884
[TBL] [Abstract][Full Text] [Related]
25. lncRNA TUG1 inhibits the cancer stem cell‑like properties of temozolomide‑resistant glioma cells by interacting with EZH2.
Cao Y; Chai W; Wang Y; Tang D; Shao D; Song H; Long J
Mol Med Rep; 2021 Jul; 24(1):. PubMed ID: 34036375
[TBL] [Abstract][Full Text] [Related]
26. Long noncoding RNA PCAT6 functions as an oncogene by binding to EZH2 and suppressing LATS2 in non-small-cell lung cancer.
Shi X; Liu Z; Liu Z; Feng X; Hua F; Hu X; Wang B; Lu K; Nie F
EBioMedicine; 2018 Nov; 37():177-187. PubMed ID: 30314898
[TBL] [Abstract][Full Text] [Related]
27. The long and short non-coding RNAs modulating EZH2 signaling in cancer.
Mirzaei S; Gholami MH; Hushmandi K; Hashemi F; Zabolian A; Canadas I; Zarrabi A; Nabavi N; Aref AR; Crea F; Wang Y; Ashrafizadeh M; Kumar AP
J Hematol Oncol; 2022 Mar; 15(1):18. PubMed ID: 35236381
[TBL] [Abstract][Full Text] [Related]
28. Inhibition of enhancer of zeste homolog 2 (EZH2) overcomes enzalutamide resistance in castration-resistant prostate cancer.
Bai Y; Zhang Z; Cheng L; Wang R; Chen X; Kong Y; Feng F; Ahmad N; Li L; Liu X
J Biol Chem; 2019 Jun; 294(25):9911-9923. PubMed ID: 31085587
[TBL] [Abstract][Full Text] [Related]
29. Androgen receptor drives hepatocellular carcinogenesis by activating enhancer of zeste homolog 2-mediated Wnt/β-catenin signaling.
Song H; Yu Z; Sun X; Feng J; Yu Q; Khan H; Zhu X; Huang L; Li M; Mok MTS; Cheng ASL; Gao Y; Feng H
EBioMedicine; 2018 Sep; 35():155-166. PubMed ID: 30150059
[TBL] [Abstract][Full Text] [Related]
30. EZH2-mediated epigenetic suppression of SH3BGRL potently inhibits lung cancer progression.
Liu Z; Xu W; Tan X; Li C
Biochem Biophys Res Commun; 2021 Apr; 548():53-59. PubMed ID: 33631674
[TBL] [Abstract][Full Text] [Related]
31. Simvastatin is beneficial to lung cancer progression by inducing METTL3-induced m6A modification on EZH2 mRNA.
Chen WW; Qi JW; Hang Y; Wu JX; Zhou XX; Chen JZ; Wang J; Wang HH
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4263-4270. PubMed ID: 32373962
[TBL] [Abstract][Full Text] [Related]
32. Loss of long noncoding RNA FOXF1-AS1 regulates epithelial-mesenchymal transition, stemness and metastasis of non-small cell lung cancer cells.
Miao L; Huang Z; Zengli Z; Li H; Chen Q; Yao C; Cai H; Xiao Y; Xia H; Wang Y
Oncotarget; 2016 Oct; 7(42):68339-68349. PubMed ID: 27577075
[TBL] [Abstract][Full Text] [Related]
33. MicroRNA-130-5p promotes invasion as well as migration of lung adenocarcinoma cells by targeting the EZH2 signaling pathway.
Zhang G; Wu YJ; Yan F
Eur Rev Med Pharmacol Sci; 2019 Nov; 23(21):9480-9488. PubMed ID: 31773700
[TBL] [Abstract][Full Text] [Related]
34. MicroRNA-4465 suppresses tumor proliferation and metastasis in non-small cell lung cancer by directly targeting the oncogene EZH2.
Sun J; Tian X; Lu SQ; Hu HB
Biomed Pharmacother; 2017 Dec; 96():1358-1362. PubMed ID: 29169732
[TBL] [Abstract][Full Text] [Related]
35. Downregulation of hsa_circ_0026123 suppresses ovarian cancer cell metastasis and proliferation through the miR‑124‑3p/EZH2 signaling pathway.
Yang X; Wang J; Li H; Sun Y; Tong X
Int J Mol Med; 2021 Feb; 47(2):668-676. PubMed ID: 33416105
[TBL] [Abstract][Full Text] [Related]
36. LINC00511 promotes the progression of non-small cell lung cancer through downregulating LATS2 and KLF2 by binding to EZH2 and LSD1.
Zhu FY; Zhang SR; Wang LH; Wu WD; Zhao H
Eur Rev Med Pharmacol Sci; 2019 Oct; 23(19):8377-8390. PubMed ID: 31646568
[TBL] [Abstract][Full Text] [Related]
37. EZH2-mediated Epigenetic Silencing of miR-29/miR-30 targets LOXL4 and contributes to Tumorigenesis, Metastasis, and Immune Microenvironment Remodeling in Breast Cancer.
Yin H; Wang Y; Wu Y; Zhang X; Zhang X; Liu J; Wang T; Fan J; Sun J; Yang A; Zhang R
Theranostics; 2020; 10(19):8494-8512. PubMed ID: 32754259
[TBL] [Abstract][Full Text] [Related]
38. Long intergenic non-protein coding RNA 319 aggravates lung adenocarcinoma carcinogenesis by modulating miR-450b-5p/EZH2.
Zhang ZW; Chen JJ; Xia SH; Zhao H; Yang JB; Zhang H; He B; Jiao J; Zhan BT; Sun CC
Gene; 2018 Apr; 650():60-67. PubMed ID: 29408583
[TBL] [Abstract][Full Text] [Related]
39. MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of zeste homolog 2.
Zhang JG; Guo JF; Liu DL; Liu Q; Wang JJ
J Thorac Oncol; 2011 Apr; 6(4):671-8. PubMed ID: 21270667
[TBL] [Abstract][Full Text] [Related]
40. EZH2 enhances expression of CCL5 to promote recruitment of macrophages and invasion in lung cancer.
Xia L; Zhu X; Zhang L; Xu Y; Chen G; Luo J
Biotechnol Appl Biochem; 2020 Nov; 67(6):1011-1019. PubMed ID: 31855281
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
